·416·心血管病学进展2021年5月第42卷第5期AdvCardiovascDis,May2021,Vol.42,No.5
Apher,2020,35(1):9-17.[48]BanerjeeP,ChanKC,TarabocchiaM,etal.FunctionalanalysisofLDLR(low-
[42]diMinnoMND,GentileM,diMinnoA,etal.Changesincarotidstiffnessinpatientsdensitylipoproteinreceptor)variantsinpatientlymphocytestoassesstheeffect
withfamilialhypercholesterolemiatreatedwithEvolocumab?:aprospectivecohortofevinacumabinhomozygousfamilialhypercholesterolemiapatientswitha
study[J].NutrMetabCardiovascDis,2020,30(6):996-1004.spectrumofLDLRactivity[J].ArteriosclerThrombVascBiol,2019,39(11):
[43]MahmoodT,MinnierJ,ItoMK,etal.Discordantresponsesofplasmalow-density2248-2260.
lipoproteincholesterolandlipoprotein(a)toalirocumab:apooledanalysisfrom[49]RaalFJ,RosensonRS,ReeskampLF,etal.Evinacumabforhomozygousfamilial
10ODYSSEYphase3studies[J].EurJPrevCardiol,2020,Apr10;hypercholesterolemia[J].NEnglJMed,2020,383(8):711-720.
2047487320915803．DOI:10．1177/2047487320915803．Onlineaheadofprint.[50]朱春霞,荆恒攀,周莉,等.新型调脂药BempedoicAcid的临床研究进展
[44]RaalFJ,KallendD,RayKK,etal.Inclisiranforthetreatmentofheterozygous[J].中国处方药,2019,17(4):12-14.
familialhypercholesterolemia[J].NEnglJMed,2020,382(16):1520-1530.[51]RayKK,BaysHE,CatapanoAL,etal.Safetyandefficacyofbempedoicacidto
[45]BrandtsJ,RayKK.SmallinterferingRNAtoproproteinconvertasesubtilisin/reduceLDLcholesterol[J].NEnglJMed,2019,380(11):1022-1032.
kexintype9:transformingLDL-cholesterol-loweringstrategies[J].CurrOpin[52]MarrsJC,AndersonSL.Bempedoicacidforthetreatmentofdyslipidemia[J].
Lipidol,2020,31(4):182-186.DrugsContext,2020,9:2020-6-5.
[46]KoishiR,AndoY,OnoM,etal.ANGPTL3regulateslipidmetabolisminmice[53]GaudetD,DurstR,LeporN,etal.Usefulnessofgemcabeneinhomozygous
[J].NatGenet,2002,30(2):151-157.familialhypercholesterolemia(fromCOBALT-1)[J].AmJCardiol,2019,124
[47]DeweyFE,GusarovaV,DunbarRL,etal.Geneticandpharmacologic(12):1876-1880．
inactivationofANGPTL3andcardiovasculardisease[J].NEnglJMed,2017,
收稿日期:2020-10-12
377(3):211-221.
■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■
(上接第410页)
[13]SegersVFM,HeidbuchelH.Evidenceandindicationsforpercutaneousclosurepreventionandmanagementofperiproceduralandpostproceduralcomplications
oftheleftatrialappendage[J].RevEspCardiol(EnglEd),2018,71(9):700-[J].CardElectrophysiolClin,2020,12(1):67-75.
702.[22]TuragamMK,VelagapudiP,KarS,etal.Cardiovasculartherapiestargetingleft
[14]ReddyVY,GibsonDN,KarS,etal.Post-approvalU.S.experiencewithleftatrialappendage[J].JAmCollCardiol,2018,72(4):448-463.
atrialappendageclosureforstrokepreventioninatrialfibrillation[J].JAmColl[23]NguyenA,GalletR,RiantE,etal.Perideviceleakafterleftatrialappendage
Cardiol,2017,69(3):253-261.closure:incidence,riskfactors,andclinicalimpact[J].CanJCardiol,2019,35
[15]ZwirnerJ,BayerR,H?drichC,etal.Pulmonaryarteryperforationandcoronary(4):405-412.
airembolism—Twofataloutcomesinpercutaneousleftatrialappendage[24]DellaRoccaDG,HortonRP,TarantinoN,etal.Useofanovelseptaloccluder
occlusion[J].IntJLegalMed,2017,131(1):191-197.deviceforleftatrialappendageclosureinpatientswithpostsurgicaland
[16]Mobius-WinklerS,MajunkeN,SandriM,etal.Percutaneousleftatrialpostlariatleaksoranatomiesunsuitableforconventionalpercutaneousocclusion
appendageclosure:technicalaspectsandpreventionofperiprocedural[J].CircCardiovascInterv,2020,13(10):e009227.
complicationswiththewatchmandevice[J].WorldJCardiol,2015,7(2):65-[25]MohantyS,GianniC,TrivediC,etal.Riskofthromboemboliceventsafter
75.percutaneousleftatrialappendageligationinpatientswithatrialfibrillation:
[17]LempereurM,AminianA,FreixaX,etal.Device-associatedthrombusformationlong-termresultsofamulticenterstudy[J].HeartRhythm,2020,17(2):175-
afterleftatrialappendageocclusion:asystematicreviewofeventsreportedwith181.
theWatchman,theAmplatzerCardiacPlugandtheAmulet[J].Catheter[26]DellaRoccaDG,HortonRP,diBiaseL,etal.Firstexperienceoftranscatheter
CardiovascInterv,2017,90(5):E111-E121.leakocclusionwithdetachablecoilsfollowingleftatrialappendageclosure[J].
[18]Black-MaierE,PicciniJP,GrangerCB.Leftatrialappendageclosure:atherapyJACCCardiovascInterv,2020,13(3):306-319.
uniquelysuitedforspecificpopulationsofpatientswithatrialfibrillation[J].J[27]MohantyS,TrivediC,BeheiryS,etal.Venousaccess-siteclosurewithvascular
CardiovascElectrophysiol,2019,30(12):2968-2976.closuredevicevs.manualcompressioninpatientsundergoingcatheterablation
[19]BoersmaLV,InceH,KischeS,etal.Evaluatingreal-worldclinicaloutcomesinorleftatrialappendageocclusionunderuninterruptedanticoagulation:a
atrialfibrillationpatientsreceivingtheWATCHMANleftatrialappendagemulticentreexperienceonefficacyandcomplications[J].Europace,2019,21
closuretechnology:final2-yearoutcomedataoftheEWOLUTIONtrialfocusing(7):1048-1054.
onhistoryofstrokeandhemorrhage[J].CircArrhythmElectrophysiol,2019,12[28]李玉豪,雷长城.经皮左心耳封堵术在预防心房颤动患者脑卒中的应用前
(4):e006841.景[J].心血管病学进展,2019,40(8):1083-1087.
[20]Torres-SauraF,Pérez-dePradoA,Romero-VazquiánezM,etal.Catheter-based[29]KavinskyCJ,KusumotoFM,BavryAA,etal.SCAI/ACC/HRSinstitutionaland
closureofresidualleaksafterpercutaneousocclusionoftheleftatrialappendageoperatorrequirementsforleftatrialappendageocclusion[J].JAmCollCardiol,
withWATCHMANdevice:twocases[J].RevEspCardiol(EnglEd),2020,732016,67(19):2295-2305．
(3):262-263.
收稿日期:2020-12-15
[21]WilkinsB,FukutomiM,deBackerO,etal.Leftatrialappendageclosure: |
|
